Megan Cheah
JOURNALIST
Megan was a journalist with The Business Times from June 2023 to June 2025. She covered companies and markets, with a focus on healthcare, medtech and pharmaceuticals. She also previously wrote about listed consumer companies. She graduated from Nanyang Technological University with a degree in communication studies.
Cutting the cord?: Events leading up to and after Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
These disclosures come as Cordlife works to resume cord-blood banking services
Lightstone Ventures, Temasek’s ClavystBio co-lead Allay Therapeutics’ US$57.5 million Series D funding
The company’s technology is used to create analgesic products that can aid patients with post-surgical pain management and recuperation
Court partially allows Goh Jin Hian’s appeal, finds he did not breach duty by not probing IPP’s red flags
Dr Goh no longer has to pay damages to the insolvent marine-fuel supplier; he was previously liable for US$146 million plus interest
The privatisation offer for this small Catalist company could cause SGX some discomfort
The proposal to take Singapore Paincare private comes a mere five years after IPO, and highlights the local bourse’s chronic lack of...
Singapore stocks fall as Trump tariffs resume for now; STI retreats 0.6%
Across the broader market, decliners beat gainers 248 to 209, with 1.3 billion securities worth S$3.3 billion changing hands
Measures to address medical inflation could soften revenue, but issues have abated significantly: IHH Healthcare
CEO says group is now negotiating directly with insurers, offering more packages and discounts
SingHealth Duke-NUS’ AI spinoff inks MOUs with Roche, ST Engineering to improve healthcare operations
Possible uses for the Enigma platform include accelerating clinical trial recruitment, checking specialised data
Perennial to invest one billion yuan to open two hospitals in Guangzhou
This includes a wholly foreign-owned general hospital, the group’s second in China
‘A GPS for stem cells’: TargaZyme’s Singapore CEO wants to cure cancer
The company aims to develop cancer immunotherapies using its cell efficacy multiplier technology.
Reit privatisation unsurprising amid higher-for-longer interest rates, but investment opportunities remain: SGX equities head
Real estate investment trusts have a lower correlation with macro uncertainties compared to equities and other asset classes, making the sector a...